Pro Medicus Ltd

Discover why Pro Medicus (PME) remains a steady small‑cap in the ASX 50 ETF, its solid financials, limited growth, and hidden risks and opportunities for investors.

Pro Medicus secures $25 M U.S. contract renewals for Visage 7 Cardiology, boosting diagnostic accuracy, workflow efficiency and revenue for health systems.

Pro Medic’s new $40 M U.S. contracts boost revenue modestly, yet the real value lies in higher‑margin transaction fees, AI upsells and regulatory‑compliant edge—yet risks from customer concentration, tight regulations and fierce competition remain.

Pro Medic Ltd. (PMU) offers a leading health‑tech billing platform that cuts imaging claim time by 40% and boosts revenue cycles; its valuation at 22.5x P/E shows a discount vs. CSL and Cochlear, making it a compelling entry point for investors amid…

Pro Medicus Ltd. (ASX: PME) offers a high‑growth, software‑centric health‑tech model that boosts imaging, reporting, and appointment efficiency while meeting strict safety and regulatory standards.

Pro Medic Ltd insider trades reveal executive confidence amid market volatility – a clear guide for investors and healthcare professionals to stay informed and make data‑driven decisions.

Pro Medic Ltd. (ASX: PMED) – steady health‑tech software firm with subscription‑based revenue, high switching costs and strong local market focus, poised for incremental growth amid Australian digital‑health trends.

Pro Medic’s first‑half 2026 results show revenue growth and a healthier EPS, yet market doubts linger over fair‑value gains, regulatory shifts, and rising competition.

Pro Medicus’s H1 2026 earnings beat expectations, lifting revenue and EPS thanks to new contracts and fair‑value gains—yet shares fell amid market softness. Investors should weigh the sustained growth potential against the one‑off gains and analyst …

Pro Medic Ltd. reports a strong first‑half 2026 earnings surge: A$171.22 m net income, 163.60¢ EPS, driven by customer contracts, interest income and fair‑value gains.